|
|
|
|
|
|
StockCentral :: Community
|
|
Join in on the discussion with other like-minded investors in our community forums. Learn about the fundamental investing methodology and participate in educational workshops in the Investing forums, stay up-to-date on StockCentral news and make suggestions to the StockCentral team in Central Square, and discuss your favorite stock or recent market news in our A-Z ticker-based forums.
|
| Note: You must be a StockCentral subscriber and logged in to post messages. |
|
|
| Author |
Messages |
|
Danny Matthews
 |
| 06/13/2007 11:08 AM |
|
This is a PR Newwire release
LifeCell Corporation Receives 510(k) Clearance for Tissue Repair Product
Wednesday June 13, 8:00 am ET
BRANCHBURG, N.J., June 13 /PRNewswire-FirstCall/ -- LifeCell Corporation (Nasdaq: LIFC - News), announced today that the Company received 510(k) clearance from the United States Food and Drug Administration for Strattice(TM) tissue matrix, a novel soft tissue repair product. Like AlloDerm®, the Company's flagship reconstructive surgical product, Strattice(TM) is intended for use in soft tissue repair procedures including breast reconstruction and hernia repair.
"In animal studies sponsored by LifeCell, Strattice(TM) performed essentially equivalent to AlloDerm®, demonstrating that it allows for tissue regeneration," commented David McQuillan, Ph.D., LifeCell's Vice President of Research. "Strattice(TM) is a sterile porcine-derived tissue matrix that has been processed using the Company's proprietary technology," he added.
"Strattice(TM) broadens our current technology platform and provides an opportunity to leverage our leadership position in biological solutions for soft tissue repair," commented Paul Thomas, President and Chief Executive Officer of LifeCell Corporation. "Commercialization of Strattice(TM) will allow us to expand our business into global markets, which was extremely difficult with our human-derived products," he added.
In preparation for commercial launch, the Company is planning to initiate several clinical studies. The Strattice(TM) product should be available to surgeons on a limited basis later this year, with a commercial launch anticipated in early 2008.
|
|
Danny Matthews
Tuscola IL |
|
|
Danny Matthews
|
| 08/28/2007 2:23 PM |
|
Wachovia gave LIFC and upgrade based on the previous approval listed below. 8/28//07
Matson said Strattice, a tissue graft taken from pigs, will give LifeCell larger supplies of tissue, allowing it to cut prices and compete with cheaper products. The company's main product, AlloDerm Regenerative Tissue Matrix, is made from donated human skin.
"Strattice provides a means for LifeCell to enter new markets such as aesthetics, where ethical issues had inhibited AlloDerm use, and trauma, where tissue size limitations had constrained AlloDerm use," he said.
Strattice received marketing clearance from the U.S. Food and Drug Administration in June. |
|
Danny Matthews
Tuscola IL |
|
|
armin fields
|
| 08/31/2007 4:18 PM |
|
|
Hi Danny:
Value Line's 8-31-07 report for LIFC raised its EPS estimates for 2007, 2008 and (slightly) for the next 3-5 years. VL seems very positive about LIFC's new tissue-repair product (Strattice) which has several advantages over the company's current product (AlloDerm).
Unlike VL, all the other analysts (First Call, Zacks, Reuters, and S&P) have lowered their long-term EPS estimates. However, they all are still high, with First Call the lowest at 30.00% and VL the highest at 31.50%. Something seems way wrong with Take Stock online which is estimating an unreasonably low 0.10% EPS growth for the next 5 years. Thats one-tenth of one percent growth, and not ten percent!!
I noticed that you also lowered your SSG's EPS estimate from 25.0% to 20.0% on 3-31-07 while you increased your High PE from 25.3 to 30.0.
- How did you determine your 30.0 Hi PE estimate?
- Also, what method did you use to decide to use $19.00 as your Low Price given that the standard SSG options you got were much lower ($10.80, $7.20 and $8.20)?
Armin
|
|
Armin Fields
check out my SSG blog at
http://arminfields.wordpress.com |
|
|
Danny Matthews
|
| 08/31/2007 5:14 PM |
|
Armin, Take Stock looks at numbers only not the story behind the numbers. LIFC can grow at 30% for the forseeable future. I use the 30 PE because I have read that it is not wise to believe a stock can trade above the 30 times EPS forever. in my view this gives me a cushion against future PE compression. LIFC now trades at approx 40 times earnings. Going from 25 to 20% is just being cautious, or a margin of safety, should the company miss a quarter. I will now use the low price of $21 and not the $8 to $10 range on the SSG. I believe those lows over the past five years are not attainable with the growth explosion over that time period. As you can see they have an EPS growth of 147% over a ten year period.
With my updated SSG I use $21 as a low, (using the 52 week low). Growing sales at 40% and EPS at the current rate, (historically) I use 20% growth for a five year projection, which also gives a margin of safety. I get a U/D of 1.8 to 1. This is of course a hold at this price. today LIFC is up $1.45 mostly due to being added to the S&P 600 midcap index. |
 Attachment: LIFC.SSG
|
Danny Matthews
Tuscola IL |
|
|
|
| Note: You must be a StockCentral subscriber and logged in to post messages. |
|
|
|
ActiveForums 3.7
|
|